Release Date: 18 December 2024
Bahrain's pharmaceutical market, while smaller than its Gulf neighbors, exhibits unique characteristics shaped by its compact size and well-integrated healthcare system. The market benefits from strong government support ...
Release Date: 17 December 2024
Targeting signaling pathways, also referred to as molecular switches, has emerged as a promising strategy in the field of cancer therapy. These pathways play a crucial role in regulating a wide range of cellular processes...
Release Date: 17 December 2024
LAG-3 (lymphocyte activation gene-3) protein represents an exciting frontier in immuno-oncology and potentially autoimmune diseases. As a novel immune checkpoint target, LAG-3 inhibitors have emerged as a promising class ...
Release Date: 17 December 2024
Tetraspecific antibodies represent a novel frontier in therapeutic development, combining the targeting capabilities of multiple antibodies into a single entity. Unlike traditional antibodies that typically bind to one sp...
Release Date: 16 December 2024
The approval of sacituzumab tirumotecan in China, developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., is a significant advancement in oncology. This innovative antibody-drug conjugate (ADC) introduces a transf...
Release Date: 13 December 2024
CD40 is a co-stimulatory receptor that has garnered significant attention in tumor immunology due to its central role in bridging innate and adaptive immune responses. Expressed on antigen-presenting cells (APCs) such as ...
Release Date: 13 December 2024
The bispecific antibodies market has reached a significant milestone with approximately 15 approved products across global markets, marking the successful transition of this therapeutic class from experimental concept to ...
Release Date: 13 December 2024
The domain of cancer treatment has experienced remarkable advancements through the therapeutic application of peptides. Researchers and drug makers have formulated a range of innovative approaches to utilize the distincti...
Release Date: 07 December 2024
Dazodalibep, a fusion protein developed by Viela Bio and later acquired by Horizon Therapeutics and Amgen, is a leading candidate in the growing CD40/CD40L-targeting therapy market. This innovative therapy works by bindin...
Release Date: 07 December 2024
Frexalimab (SAR441344) is a promising second-generation investigational anti-CD40L antibody developed by Sanofi under an exclusive license from ImmuNext. It is one of the few anti-CD40L-targeting therapies progressing to ...
Release Date: 06 December 2024
Anticancer peptides (ACPs) have emerged as a promising class of therapeutics in oncology, offering targeted mechanisms to inhibit tumor growth and metastasis. Their specificity and reduced toxicity compared to traditional...
Release Date: 06 December 2024
Antibody-drug conjugates (ADCs) have emerged as a transformative force in cancer treatment, combining the specificity of monoclonal antibodies with the cytotoxic power of chemotherapy agents. This innovative approach enab...
Release Date: 06 December 2024
Targeted therapies are revolutionizing the cancer treatment landscape, offering a precise and personalized approach that is reshaping outcomes for patients worldwide. Unlike traditional chemotherapy, which indiscriminatel...
Release Date: 03 December 2024
CD40 targeted therapies have emerged as a critical focus in cancer immunotherapy, offering novel approaches to enhance immune system activation against tumors. CD40, a co-stimulatory receptor found on antigen-presenting c...
Release Date: 02 December 2024
Ziihera (zanidatamab) represents a significant advancement in the realm of bispecific antibodies, specifically targeting HER2, and signifies a notable progression in targeted cancer therapies. Its approval by the US FDA i...